MoonLake Immunotherapeutics

Historical price data

MoonLake Immunotherapeutics is a Swiss biotech focused on developing next-generation immunotherapies using its proprietary Nanobody® technology platform. The company's lead asset, sonelokimab, is a first-in-class trivalent Nanobody® targeting IL-17A and IL-17F, with a promising clinical profile in inflammatory skin and joint diseases. Following a successful merger and public listing, MoonLake is advancing sonelokimab into late-stage development, aiming to establish a new standard of care in hidradenitis suppurativa and expand into other autoimmune indications.

Proprietary Nanobody® platform for developing small, stable, multivalent antibody fragments that target inflammatory pathways, enabling potentially superior tissue penetration and target engagement compared to conventional monoclonal antibodies.

10 drugs in pipeline, 7 in Phase 3

Total raised: $60M

Competes against major pharma companies like AbbVie, Novartis, Johnson & Johnson, and UCB in dermatology and rheumatology. Key differentiation is sonelokimab's trivalent Nanobody® structure targeting both IL-17A and IL-17F, aiming for best-in-class efficacy in hidradenitis suppurativa and psoriatic arthritis.